Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectrum Pharmaceuticals has reported that the first patient has received SPI-1620 in a Phase I dose-escalation study. SPI-1620, a highly selective endothelin-B agonist, is being developed as an adjunct to cancer chemotherapy.
Subscribe to our email newsletter
The Phase I trial is an open label, dose-escalation study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma.
Rajesh Shrotriya, president and CEO of Spectrum Pharmaceuticals, said: “We believe that with further clinical development, SPI-1620 has the potential to significantly increase the efficacy of a broad range of chemotherapeutic drugs used for the treatment of solid tumors.”